<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01356290</url>
  </required_header>
  <id_info>
    <org_study_id>MUV-MEMMAT-01</org_study_id>
    <nct_id>NCT01356290</nct_id>
  </id_info>
  <brief_title>Metronomic and Targeted Anti-angiogenesis Therapy for Children With Recurrent/Progressive Medulloblastoma</brief_title>
  <acronym>MEMMAT</acronym>
  <official_title>A Phase II Study of Metronomic and Targeted Anti-angiogenesis Therapy for Children With Recurrent/Progressive Medulloblastoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with relapsed medulloblastoma have a very poor prognosis whether treated with
      conventional chemotherapy, high-dose chemotherapy with stem cell rescue, irradiation or
      combinations of these modalities. Antiangiogenetic therapy has emerged as new treatment
      option in solid malignancies. The frequent, metronomic schedule targets both proliferating
      tumor cells and endothelial cells, and minimizes toxicity. In this study the investigators
      will evaluate the use of biweekly intravenous bevacizumab in combination with five oral drugs
      (thalidomide, celecoxib, fenofibrate, and alternating cycles of daily low-dose oral etoposide
      and cyclophosphamide), augmented with alternating courses of intrathecal etoposide and
      liposomal cytarabine. The aim of the study is to extend therapy options for children with
      recurrent or progressive medulloblastoma, for whom no known curative therapy exists, by
      prolonging survival while maintaining good quality of life. The primary objective of the
      MEMMAT trial is to evaluate the activity of this multidrug antiangiogenic approach in these
      heavily pretreated children and young adults. Additionally, progression-free survival (PFS),
      overall survival (OS), as well as feasibility and toxicity will be examined.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy</measure>
    <time_frame>8 years</time_frame>
    <description>Response rate (Complete remission, partial response, stable disease =[CR+PR+SD]/n) 6 months after start of antiangiogenic treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival rate</measure>
    <time_frame>8 years</time_frame>
    <description>The percentage of patients in the study who are alive for a certain period of time (6, 12, 24, and 36 months) after start of treatment with an antiangiogenic multidrug-regime</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival rate</measure>
    <time_frame>8 years</time_frame>
    <description>The percentage of patients in the study who are alive with a non-progressive disease for a certain period of time (6, 12, 24, and 36 months) after start of treatment with an antiangiogenic multidrug-regime.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>8 years</time_frame>
    <description>To evaluate and document toxicities from chronic administration of these drugs at the doses prescribed in this protocol in patients with recurrent or progressive medulloblastoma. These will be descriptive in nature.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Feasibility</measure>
    <time_frame>6 years</time_frame>
    <description>To evaluate the feasibility of achieving the prescribed drug doses given the reduced bone marrow tolerance after multiple relapses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>8 years</time_frame>
    <description>Quality of Life (QoL) will be evaluated by a generic quality of life instrument for children (the KINDL®-questionnaire).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prognostic factors</measure>
    <time_frame>8 years</time_frame>
    <description>To evaluate the influence of tumor biology(histologic subgroups, metastatic stage, age at first diagnosis [&lt;3 years, &gt;3 years]), age at start of antiangiogenic therapy, sex, duration of remission prior to antiangiogenic therapy, number of recurrences.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiogenic factors</measure>
    <time_frame>8 years</time_frame>
    <description>To evaluate serum markers for in-vitro correlative studies of tumor response.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Medulloblastoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>10mg/kg, intravenous (iv), biweekly, 1 year</description>
    <other_name>Avastin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thalidomide</intervention_name>
    <description>3mg/kg, oral, daily, 1 year</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Celecoxib</intervention_name>
    <description>50-400mg, oral bid, daily, 1 year</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fenofibric acid</intervention_name>
    <description>90mg/m2, oral, daily, 1 year</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>35-50 mg/m2, oral, alternating 21-day cycles of daily oral etoposide and cyclophosphamide, 1 year</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>2.5mg/kg, oral, alternating 21-day cycles of daily oral etoposide and cyclophosphamide, 1 year</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide phosphate</intervention_name>
    <description>0.5mg, intrathecal, day 1-5, every four weeks, alternating with intrathecal liposomal cytarabine, 1 year</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liposomal cytarabine</intervention_name>
    <description>25-35mg, intrathecal, every four weeks, alternating with intrathecal etoposide phosphate, 1 year</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Relapsed or progressive medulloblastoma (at least one site of untreated recurrent
             disease)

          -  Histological confirmation of medulloblastoma at diagnosis or relapse

          -  Female or male, aged from 0 to &lt;20 years (at time of original diagnosis)

          -  Participants must have normal organ and bone marrow function (ALT &lt;5x institutional
             upper limit of normal, creatinine &lt;1.5x institutional upper limit of normal for age,
             WBC &gt;1000/mm3, platelets &gt; 20,000/mm3. Patients with values less than WBC 2000/mm3 or
             platelets 50,000/mm3 will require initiation of treatment with etoposide and
             cyclophosphamide at a lower starting dose as defined within the protocol.

          -  Karnofsky performance status ≥50. For infants and children less than 12 years of age,
             the Lansky play scale ≥50% will be used

          -  Written informed consent of patients and / or parents

        Exclusion Criteria:

          -  Active infection

          -  VP-shunt dependency

          -  Pregnancy or breast feeding

          -  Conventional chemotherapy, antiangiogenic treatment or complete irradiation of all
             disease for current relapse (surgery may be performed before antiangiogenic treatment;
             patients with sites of disease not irradiated are still eligible for the protocol)

          -  Known hypersensitivity to any of the drugs in the protocol

          -  Active peptic ulcer

          -  Any significant cardiovascular disease not controled by standard therapy e.g. systemic
             hypertension

          -  Anticipation of the need for major elective surgery during the course of the study
             treatment

          -  Any disease or condition that contraindicates the use of the study
             medication/treatment or places the patient at an unacceptable risk of experiencing
             treatment-related complications

          -  Non-healing surgical wound

          -  A bone fracture that has not satisfactorily healed
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>19 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreas Peyrl, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Vienna</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Monika Chocholous, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Medical University of Vienna</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andreas Peyrl, MD</last_name>
    <phone>+43 1 40400</phone>
    <phone_ext>32320</phone_ext>
    <email>andreas.peyrl@meduniwien.ac.at</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Irene Slavc, MD</last_name>
    <phone>+43 1 40400</phone>
    <phone_ext>32320</phone_ext>
    <email>irene.slavc@meduniwien.ac.at</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ann &amp; Robert H. Lurie Children's Hospital of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611-2605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emily Golbeck</last_name>
      <email>egolbeck@luriechildrens.org</email>
    </contact>
    <contact_backup>
      <last_name>Kevin Ritt</last_name>
      <email>kritt@luriechildrens.org</email>
    </contact_backup>
    <investigator>
      <last_name>Jason Fangusaro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rishi Lulla, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stewart Goldman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute and Boston Children's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joanne Kennedy, RN, BA</last_name>
      <phone>617-632-5324</phone>
      <email>Joanne_Kennedy1@dfci.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Mark Kieran, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of Graz</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elisabeth Hulla-Gumbsch</last_name>
      <phone>+43 316 385</phone>
      <phone_ext>82686</phone_ext>
      <email>elisabeth.hulla-gumbsch@klinikum-graz.at</email>
    </contact>
    <investigator>
      <last_name>Christian Urban, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yvonne Ennemoser, MSc</last_name>
      <phone>+43 512 504</phone>
      <phone_ext>23605</phone_ext>
      <email>yvonne.ennemoser@tirol-kliniken.at</email>
    </contact>
    <investigator>
      <last_name>Bernhard Meister, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kepler Universitätsklinikum Med Campus IV</name>
      <address>
        <city>Linz</city>
        <zip>4020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martina Winkler</last_name>
      <phone>+43 5 7680 84</phone>
      <phone_ext>24302</phone_ext>
      <email>martina.winkler@gespag.at</email>
    </contact>
    <investigator>
      <last_name>Georg Ebetsberger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Salzburger Universitätsklinikum</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Agnes Gamper, MD</last_name>
      <phone>+43 662 448257</phone>
      <phone_ext>759</phone_ext>
      <email>a.gamper@salk.at</email>
    </contact>
    <investigator>
      <last_name>Agnes Gamper, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Peyrl, MD</last_name>
      <phone>+43 1 40400</phone>
      <phone_ext>32320</phone_ext>
      <email>andreas.peyrl@meduniwien.ac.at</email>
    </contact>
    <contact_backup>
      <last_name>Irene Slavc, MD</last_name>
      <phone>+43 1 40400</phone>
      <phone_ext>32320</phone_ext>
      <email>irene.slavc@meduniwien.ac.at</email>
    </contact_backup>
    <investigator>
      <last_name>Andreas Peyrl, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Irene Slavc, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Brno</name>
      <address>
        <city>Brno</city>
        <zip>61300</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandra Martincekova, MD</last_name>
      <phone>+420532234755</phone>
      <email>Martincekova.Alexandra@fnbrno.cz</email>
    </contact>
    <investigator>
      <last_name>Jaroslav Sterba, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zdenek Pavelka, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Motol University Hospital Prague</name>
      <address>
        <city>Prague</city>
        <zip>15006</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Klara Hruba</last_name>
      <phone>+42 0224436401</phone>
      <email>klara.hruba@fnmotol.cz</email>
    </contact>
    <investigator>
      <last_name>David Sumerauer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University hospital Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karsten Nysom, MD</last_name>
      <phone>+45 3545 0809</phone>
      <email>karsten.nysom@regionh.dk</email>
    </contact>
    <investigator>
      <last_name>Karsten Nysom, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alicia Probst</last_name>
    </contact>
    <contact_backup>
      <phone>+33 3 20 29 55 68</phone>
      <email>a-probst@o-lambret.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Pierre Leblond, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska Universitetssjukhuset</name>
      <address>
        <city>Göteborg</city>
        <zip>416 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karin Fritzson</last_name>
      <phone>+46 31 343 58 65</phone>
      <email>karin.fritzson@vgregion.se</email>
    </contact>
    <contact_backup>
      <last_name>Anna Schröder- Håkansson</last_name>
      <phone>+46 31 343 58 65</phone>
      <email>anna.schroder_hakansson@vgregion.se</email>
    </contact_backup>
    <investigator>
      <last_name>Magnus Sabel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Birgitta Lannering, Prof</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitetssjukhuset Linköping</name>
      <address>
        <city>Linköping</city>
        <zip>581 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Birgitta Hellström</last_name>
      <phone>+46 10 103 13 54</phone>
      <email>birgitta.hellstrom@regionostergotland.se</email>
    </contact>
    <contact_backup>
      <last_name>Pernilla Augustsson</last_name>
      <phone>+46 10-103 13 50</phone>
      <email>pernilla.augustsson@regionostergotland.se</email>
    </contact_backup>
    <investigator>
      <last_name>Irene Devenney, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Skånes universitetssjukhus</name>
      <address>
        <city>Lund</city>
        <zip>221 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yvonne Håkansson</last_name>
      <phone>+46 46-17 80 64</phone>
      <email>Yvonne.Hakansson@skane.se</email>
    </contact>
    <contact_backup>
      <last_name>Simon Johansson</last_name>
      <phone>+46 46-17 80 64</phone>
      <email>simon.johansson@skane.se</email>
    </contact_backup>
    <investigator>
      <last_name>Helena Mörse, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <zip>SE-171 76</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carina Rinaldo</last_name>
      <phone>+46 8 517 701 51</phone>
      <email>carina.rinaldo@karolinska.se</email>
    </contact>
    <contact_backup>
      <last_name>Yvonne Copeland</last_name>
      <phone>+46 8 517 724 84</phone>
      <email>yvonne.copeland-wahlo@karolinska.se</email>
    </contact_backup>
    <investigator>
      <last_name>Stefan Holm, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Norrlands Universitetssjukhus</name>
      <address>
        <city>Umeå</city>
        <zip>901 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marita Wikström-Larsson</last_name>
      <phone>+46 90-785 02 44</phone>
      <email>Marita.Vikstrom.Larsson@vll.se</email>
    </contact>
    <investigator>
      <last_name>Mattias Mattsson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Akademiska sjukhuset</name>
      <address>
        <city>Uppsala</city>
        <zip>751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katarina Vallin</last_name>
      <phone>+46 18 611 34 94</phone>
      <email>katarina.vallin@akademiska.se</email>
    </contact>
    <investigator>
      <last_name>Anders Öberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Sweden</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 17, 2011</study_first_submitted>
  <study_first_submitted_qc>May 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 19, 2011</study_first_posted>
  <last_update_submitted>May 15, 2017</last_update_submitted>
  <last_update_submitted_qc>May 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Andreas Peyrl</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Medulloblastoma</keyword>
  <keyword>Relapse</keyword>
  <keyword>Children</keyword>
  <keyword>antiangiogenic</keyword>
  <keyword>metronomic</keyword>
  <keyword>intrathecal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Medulloblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Celecoxib</mesh_term>
    <mesh_term>Fenofibric acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

